Enzymatic synthesis may be more sustainable for large-scale oligonucleotide manufacturing than traditional solid-phase techniques.

Modern medicine depends on large, information-rich molecules such as peptides and oligonucleotides. These molecules carry biological instructions that can be directed toward specific disease pathways.

Matthew Hayes (Left) is the Chief Technology Officer and founder at Evonetix, a groundbreaking gene synthesis technology company created in 2015, where he deploys his expertise in multi-disciplinary ...